Pembrolizumab in advanced osteosarcoma: results of a single-arm, open-label, phase 2 trial
ConclusionIn this phase 2 study in advanced osteosarcoma, pembrolizumab was well-tolerated but did not show clinically significant antitumor activity. Future trials with immunomodulatory agents in osteosarcoma should explore combination strategies in patients selected based on molecular profiles associated with response.
Source: Cancer Immunology, Immunotherapy - Category: Cancer & Oncology Source Type: research
More News: Allergy & Immunology | Bone Cancers | Cancer | Cancer & Oncology | Genetics | Immunotherapy | Nanotechnology | Osteosarcoma | Study